Compare · regulatory status only
Compounded tirzepatide vs Mounjaro and Zepbound: what is actually different?
The short answer
Mounjaro and Zepbound are FDA-approved tirzepatide drugs made by Eli Lilly and legal by prescription. Compounded tirzepatide copies were broadly permitted only during the FDA-declared shortage; after the FDA called the shortage resolved in late 2024 - a determination a federal court upheld - the permission ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. Gray-market 'research' vials are a third thing entirely: unapproved, unregulated, and the subject of FDA warning letters.
Status comparison, not advice - Peptlas compares legality and oversight, never effects. Published Aug 27, 2026 (ET) · sources below
Side by side
| Compounded tirzepatide | Mounjaro / Zepbound | |
|---|---|---|
| Approval status | Not an approved product - a copy compounded under pharmacy rules | FDA-approved drugs (Mounjaro, Zepbound) |
| Legal to obtain today | Routine copies no longer permitted - permission ended Feb 18, 2025 (503A) / Mar 19, 2025 (503B); narrow patient-specific exception only | Yes, by prescription |
| The shortage question | FDA declared the shortage resolved in late 2024; a federal court upheld that determination in 2025 | Supply is the manufacturer's ordinary obligation |
| Quality oversight | Pharmacy/outsourcing-facility standards; the product itself was never FDA-reviewed | Full GMP manufacturing, approved dosing, pens and vials |
| Enforcement | FDA warning letters to compounders and telehealth marketers of unapproved GLP-1s | — |
| What changes next | FDA's proposed permanent 503B exclusion - comments closed Jul 30, 2026, decision pending | Nothing pending |
Why tirzepatide's window closed first
The compounding permissions for tirzepatide and semaglutide both hung on their shortage declarations, and tirzepatide's ended first: the FDA declared its shortage resolved in late 2024, litigation followed, and a federal court upheld the agency's determination - so enforcement discretion ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities, weeks ahead of semaglutide's dates. The dated, sourced timeline lives on the compounded tirzepatide status page; the general mechanism is explained in what is FDA enforcement discretion.
From here both molecules share one pending question: the FDA's proposal to exclude them - with liraglutide - from the 503B bulks list permanently. Comments closed July 30, 2026; the final determination can publish any business day, and the alert list hears about it the day it does.
What this comparison is not
Regulatory status, oversight, and legality only - no claims about effectiveness, safety, or which product anyone should use. For unit arithmetic on compounded or gray-market vials, the tirzepatide reconstitution calculator computes draws on numbers you enter and suggests nothing.
Asked and answered
- Is compounded tirzepatide still legal?
- Routine compounded copies are not - the shortage-based permission ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities, and a federal court upheld the FDA's underlying shortage determination. A narrow patient-specific 503A exception for a documented clinical need remains.
- What is the difference between Mounjaro and Zepbound?
- Both are Eli Lilly's FDA-approved tirzepatide - approved for different indications and marketed under different names. As regulatory objects they are the same tier: approved drugs, legal by prescription, made under full pharmaceutical oversight.
- Is tirzepatide banned for athletes?
- No. Tirzepatide is not prohibited by WADA; it was added to the WADA Monitoring Program effective January 1, 2026, which means usage is tracked but not sanctioned.
Sources
Keep going
Get alerted when any status changes
One short, human-verified email whenever an official status changes. No spam, no selling.